Applied Filters
Roche buys fibrotic diseases biotech in $1.4bn deal
Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Merck and Evotec strike CRISPR licensing deal
Merck has agreed to license its CRISPR gene-editing technology to German biotech company Evotec.
EPO upholds validity of eye transplant patent
Lawyers representing Italian medical devices company iVis Technologies have welcomed a decision of the European Patent Office to confirm the validity of one of the company’s patents, and are now pressing ahead with infringement claims against a German rival.
Pfizer: ‘Don’t be catfished by counterfeit drugs’
Pfizer UK has launched a new social media campaign urging people not to be “catfished” into buying counterfeit drugs.
CMA alleges collusion allowed 1,800% hike in Aspen drug pricing
African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.
Sandoz secures victory against GSK in passing off case
The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.
UK parliament report reveals threat to medical supplies post-Brexit
An independent parliamentary report has today, September 27, revealed that the UK’s health ministry remains unsure whether the country’s health service can fully withstand the impact of a no-deal Brexit next month.
UK Labour promises public generics company, compulsory drug licensing
Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.
EU parliament challenges EPO on plant patentability
The European Parliament has said that the internal rules of the European Patent Office “must not undermine democratic political control of European patent law”.
Oxford Nanopore signs CRISPR licence
UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.
